Akkermansia muciniphila vs Larazotide
Two gut-barrier approaches on completely different routes — a bacterium that rebuilds the mucin layer with a mixed but genuinely positive human RCT record, and a synthetic tight-junction regulator that failed its pivotal trial.
Akkermansia muciniphila
Pasteurized Akkermansia, Muc(T)
The founding human RCT was small (32 completers) and positive only for the pasteurized strain, not live bacteria; a larger 2026 follow-up in metabolic syndrome missed its primary endpoint while a separate 2026 maintenance trial confirmed a real effect — and live capsules, which is mostly what's sold as a 'probiotic,' have essentially no human trial data of their own.
Full Akkermansia muciniphila evidence reviewLarazotide
AT-1001
A tight-junction regulator with real celiac Phase 2 data — but its pivotal Phase 3 failed, and the supplement use runs far ahead of the evidence.
Full Larazotide evidence reviewSide by side
| Akkermansia muciniphila | Larazotide | |
|---|---|---|
| Marketed for | Gut barrier integrity, metabolic syndrome, insulin sensitivity | Leaky gut, celiac disease |
| Evidence grade | Clinical data | Clinical data |
| Family | Immune & inflammation | Immune / metabolic |
| Key human source | Depommier 2019 proof-of-concept RCT, Nat Med | Leffler, Gastroenterology 2015 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Akkermansia has real, if mixed, positive human RCT data — the founding trial showed metabolic improvements from the pasteurized strain, though a larger follow-up missed its primary endpoint. Larazotide's real Phase 2 celiac signal never converted into a Phase 3 win. Different targets entirely: Akkermansia targets the mucin layer and metabolic markers, larazotide targets the tight junctions themselves.
Akkermansia muciniphila fits if
Metabolic markers under a gut-barrier framing are the target, and you're buying the pasteurized form the trials actually used.
Larazotide fits if
Celiac-specific tight-junction regulation is the specific interest, understanding the pivotal trial for that exact use failed.
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Larazotide availability before ordering.
